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p21HPV type 58 (HPV-58) is the third most common HPV type in cervical cancer from Eastern Asia, yet little is
known about how it promotes carcinogenesis. In this study, we demonstrate that HPV-58 E7 signiﬁcantly
promoted the proliferation and extended the lifespan of primary human keratinocytes (PHKs). HPV-58 E7
abrogated the G1 and the postmitotic checkpoints, although less efﬁciently than HPV-16 E7. Consistent with
these observations, HPV-58 E7 down-regulated the cellular tumor suppressor pRb to a lesser extent than
HPV-16 E7. Similar to HPV-16 E7 expressing PHKs, Cdk2 remained active in HPV-58 E7 expressing PHKs
despite the presence of elevated levels of p53 and p21. Interestingly, HPV-58 E7 down-regulated p130 more
efﬁciently than HPV-16 E7. Our study demonstrates a correlation between the ability of down-regulating
pRb/p130 and abrogating cell cycle checkpoints by HPV-58 E7, which also correlates with the biological risks
of cervical cancer progression associated with HPV-58 infection.
© 2009 Elsevier Inc. All rights reserved.Introduction
The high-risk HPV types are commonly associated with lesions
that can progress into cervical carcinoma, which is one of the leading
causes of cancer death in women, worldwide (zur Hausen, 2002). The
oncogenic properties of high-risk HPVs primarily reside in the E6 and
E7 genes. The ability of high-risk HPV E6 and E7 proteins to promote
the degradation of tumor suppressors p53 and pRb, respectively, has
been suggested as a mechanism by which HPV induces cellular
transformation (reviewed in (Fan and Chen, 2004)). The E7 proteins
from high-risk HPVs also bind and target other Rb family members,
p107 and p130, for degradation (Dyson et al., 1992; Gonzalez et al.,
2001; Jones and Munger, 1997).
p53 and pRb family members regulate cell cycle checkpoints and
maintain genomic stability (Burkhart and Sage, 2008; Stewart and
Pietenpol, 2001). p53 controls these processes mainly by regulating
transcription of target genes (Levrero et al., 2000). One of the most
important targets of p53 for cell cycle regulation is p21, which is a
universal inhibitor of cyclin and cyclin-dependent kinase (Cdk)
(Xiong et al., 1993). pRb binds to E2F and inhibits its transcriptional
activation of genes, including cyclin A and cyclin E, which aret fax: +1 508 856 6797. X. Yu,
en), yuxp@sdu.edu.cn (X. Yu).
ll rights reserved.important for the G1-to-S phase transition (Cobrinik, 2005). Inacti-
vation of p53 and Rb family members by HPV E6 and E7 abrogates cell
cycle checkpoints and induces genomic instability, which is believed
to be important for cervical carcinogenesis (reviewed in (Fan and
Chen, 2004)).
Worldwide, HPV types 16 and 18 (HPV-16 and -18) together
account for approximately 70% of all cervical cancers (Clifford et al.,
2006). Although we have already learned a lot about the mechanism
by which several high-risk HPV types such as HPV-16 and -18 induce
cellular transformation, little is known about how other high-risk,
cervical cancer-related HPV types promote carcinogenesis. With the
availability of HPV vaccines for HPV-16 and -18, it is important to
devote some of our effort to study other high-risk HPV types. HPV-58
is the third most common HPV type in cervical cancer from Eastern
Asia, accounting for 9.8% of cervical cancer (Parkin et al., 2008). The
regional importance of HPV-58 in Eastern Asia can also been seenwith
their prevalence associated with normal cytology, low-grade squa-
mous intraepithelial lesion (LSIL), and high-grade squamous intrae-
pithelial lesion (HSIL) (Parkin et al., 2008). Speciﬁcally, in Eastern
Asia, HPV-58 is the third most common HPV type in women with
normal cytology or LSIL, and the second most common HPV type in
women with HSIL. The propensity of HPV-58 infected individuals to
progress to cervical cancer is lower than those of HPV-16 infected
patients (Parkin et al., 2008). A recent study demonstrated the ability
of HPV-58 to immortalize PHKs, the E6 protein of HPV-58 to bind PDZ
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Muench et al., 2009). However, these HPV functions do not seem to be
reliable predictors for carcinogenic behavior of HPV in the cervix. So
far, we know nothing about the biological activities of HPV-58 E7.
In the present study, we explored the biological activities of HPV-
58 E7 in PHKs. Our results demonstrate that HPV-58 E7 promotes cell
proliferation, extends lifespan of PHKs, and abrogates cell cycle
checkpoints, though does so less efﬁciently than HPV-16 E7. We also
found that Cdk2 remained active in HPV-58 E7 expressing PHKs
despite the presence of elevated levels of p53 and p21. Notably, HPV-
58 E7 down-regulates both pRb and p130. Thus, there is a correlation
between the propensity of HPV-58-induced cervical cancer progres-
sion and the ability of HPV-58 E7 to target pRb/p130 that leads to
abrogation of cell cycle checkpoints.
Results
HPV-58 E7 promotes proliferation and extends the lifespan of PHKs
The HPV-58 E7 (GI No. 222386) and HPV-16 E7 (GI N0. 9627100)
are quite similar in their amino acids composition (60% identity and
75% similarity) (Fig. 1A). Like HPV-16 E7, HPV-58 E7 contains the
LXCXE pRb-binding motif, a casein kinase II (CKII) phosphorylation
motif, and two Cys-X-X-Cys motifs. Stable cell lines were created by
infection of PHKs with retroviruses containing HPV-58 E7 (PHK-58
E7) or an empty vector (PHK-Vector). PHKs expressing HPV-16 E7
(PHK-16 E7) were included in the study as a control. HPV-58 E7
expression in the stable cell lines was conﬁrmed by RT-PCR (Fig. 1B).
HPV-58 E7 promoted the proliferation of PHKs. As shown in Fig. 1C,
within 3 days, PHK-58 E7 proliferated as efﬁciently as PHK-16 E7 and
signiﬁcantly more rapidly than the vector control cells (pb0.001). HPV-Fig. 1. Proliferation and lifespan extension of PHK-58 E7. (A) Sequence alignment of HP
sequences corresponding to conserved regions (CR1, CR2 and CR3), retinoblastoma prot
Finger (ZF) domains are indicated. (B) Total RNA isolated from PHK-58 E7 and PHK-vecto
-Vector were seeded in 6-well plate at 5×104. Cell numbers were counted every 24 h.
experiment of two are shown. (D) HPV E7 expressing PHKs or control PHKs were passaged
plotted against days in culture.58 E7 also signiﬁcantly extended the lifespan of PHKs (Fig. 1D). While
the vector control PHKs stopped dividing at passage 5 or after
approximate 22 population doublings (PDs), PHKs expressing both
HPV-58 E7 and HPV-16 E7 continued to proliferate and they did not
show any crisis period. After 5 months in culture, PHK-58 E7multiplied
82 PDs while PHK-16 E7 multiplied for 90 PDs (Fig. 1D). The E7
expressing PHKs are still proliferating after 7 months in culture and so
far have multiplied beyond 100 PDs.
HPV-58 E7 abrogates cell cycle checkpoints
It is well established that HPV-16 E7 abrogates the G1 cell cycle
checkpoint (Reviewed in (McLaughlin-Drubin and Munger, 2009)). To
examine the ability of HPV-58 E7 to modulate the G1 checkpoint, we
treated PHKs expressing HPV-58 E7 with bleomycin, a radiomimetic
agent capable of inducing both single-stranded and double-stranded
DNA breaks that lead to cell cycle arrest at G1 and G2 checkpoints (Chen
and Stubbe, 2005). As expected, upon bleomycin treatment, a reduction
in thenumber of S phase cells occurred in thevector control PHKs (Fig. 2).
Other than that, there were no major changes in cell cycle proﬁle for
these cells, suggesting that PHK-Vector arrested at both G1 and G2
checkpoints uponbleomycin treatment. In contrast, PHK-58 E7 showed a
decreasednumberof cells in theG1phaseof the cell cycle (39% inPHK-58
E7vs. 52.1% inPHK-Vector) andan increase in thenumberof Sphase cells
(20.2%vs. 14.2%). These results demonstrate thatHPV-58E7canabrogate
the DNA damage-induced G1 checkpoint. Similarly, PHK-16 E7 also
showeddecreasednumber of cells in theG1phase and increasednumber
of cells in S phase (Fig. 2). HPV-16 E7 appears to be more efﬁcient in
alleviating the G1 checkpoint.
We have recently shown that in response to mitotic stress, HPV-16
E7 induces polyploidy by abrogation of the postmitotic checkpointV-58 E7 and HPV-16 E7 proteins. Similar residues are shaded in black. Amino acid
ein binding domain (pRB), casein kinase II phosphorylation domain (CKII) and Zinc
r was subjected to RT-PCR. β-actin was used as a control. (C) PHK-16 E7, -58 E7, and
Error bars represent standard deviations of the means. Data from a representative
continuously until they cease to grow or 5 months. The number of cell doublings was
Fig. 2. HPV-58 E7 abrogates cell cycle checkpoints and induces polyploidy in PHKs. Asynchronous cultures of PHK-16 E7, -58 E7 and -Vector were treated with DMSO, bleomycin
(10 μg/mL for twenty-four hours) or nocodazole (50 ng/mL for 60 h). After the feeder cells were removed, PHKs were collected, ﬁxed, stained with PI, and analyzed by ﬂow
cytometry. G1 phase, S phase, G2/M phase and polyploidy cells are indicated. Data are from a representative experiment of two.
141W. Zhang et al. / Virology 397 (2010) 139–144(Heilman et al., 2009), which could functionally prevent tetraploid
cells from entering S phase. Polyploidy has been shown to occur as an
early event in cervical carcinogenesis and to predispose the cells to
aneuploidy (Olaharski et al., 2006). Accordingly, we treated cells with
the microtubule poison nocodazole, which activates the spindle
checkpoint and subsequently the postmitotic checkpoint. After
treating with nocodazole, PHK-58 E7 showed an increase in
polyploidy compared to vector controls (26.2% vs. 10.6%, Fig. 2).
However, HPV-58 E7 is less efﬁcient than HPV-16 E7 in inducing
polyploidy (26.2% vs. 44.2%). Taken together, our results suggest that
HPV-58 E7 abrogates the postmitotic checkpoint and induces S phase
entry in cells containing tetraploid genome.
HPV-58 E7 up-regulates Cdk2 activity in PHKs
Cdk2 is amajor regulator in S phase entry, although its function can
be compensated by other Cdks in its absence (reviewed by
(Satyanarayana and Kaldis, 2009)). To explore the mechanism by
which HPV-58 E7 abrogates cell cycle checkpoint, we examined the
expression of Cdk2 and Cdk2-associated cyclins as well as its kinase
activity in PHK-58 E7. As shown in Fig. 3A, the steady-state levels ofCdk2 were up-regulated for approximately 10-fold in PHK-58 E7 or
PHK-16 E7. The regulatory partners of Cdk2, cyclin A and cyclin E,were
also increased in these cells (Fig. 3A). These results are consistent with
the previous observations of E7 fromHPV-16 and some other potential
high-riskHPV types ((Mansour et al., 2007) and references therein). In
contrast, there was no signiﬁcant difference in the steady-state levels
of Cdk6 between E7 expressing PHKs and the vector control PHKs.
Cdk6, or structurally and functionally similar Cdk4, is the partner of D-
type cyclins and an early G1 checkpoint regulator. Because pRb, the E7
degradation target, seems to be the only essential substrate for Cdk6 or
Cdk4, they are not expected to be up-regulated by HPV E7.
What is more important to note is the up-regulation of the Cdk2-
associated kinase activity in E7-expressing PHKs (for more than 2-
fold) as compared with the vector control cells (Fig. 3B). There were
no signiﬁcant differences between HPV-16 E7 and HPV-58 E7
expressing PHKs in Cdk2-associated kinase activities. In contrast and
consistent with the expression levels, the kinase activity of Cdk6 were
similar in E7 and vector containing PHKs (Fig. 3B). These results
suggest a role of Cdk2 and its associated cyclins in abrogation of cell
cycle checkpoint induced by HPV-58 E7. However, since HPV-58 E7 is
less efﬁcient in abrogating cell cycle checkpoints butmaintains similar
Fig. 3. Expression and activities of cyclins and Cdks in PHK-58 E7. (A) 50 μg of whole cell
extracts of PHK-58 E7, -16 E7, and -Vector were resolved by SDS-PAGE and examined
by Western blot with anti-Cdk2, -cyclin E, -cyclin A, and -Cdk6 antibodies as indicated.
A representative β-actin blot is shown as a loading control. (B) Elevated Cdk2 activity in
PHK-58 E7. 100 μg of total protein extracts of PHK-58 E7, -16 E7, and -Vector were
immunoprecipitated with anti-Cdk2 and anti-Cdk6 antibodies respectively, in vitro
kinase assay were performed with full length Rb protein as a substrate. Data are from a
representative experiment of three.
Fig. 4. Expression of p53 and pRb family members in PHK-58 E7. 50 μg of whole cell
extracts of PHK-58 E7, -16 E7, and -Vector were resolved by SDS-PAGE and examined
byWestern blot analysis with (A) anti-p53 and anti p21 antibodies. (B) Anti-pRb family
member antibodies. For the p130 blot, the upper band is believed to be a non-speciﬁc
cross-reaction from an unknown protein and is marked with a star. A representative β-
actin blot is shown as a loading control. Data are from a representative experiment of at
least three.
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Cdk2 does not appears to be the limiting factor.
Up-regulation of p53 and p21 in HPV-58 E7 expressing PHKs
p53 plays a key role in mediating both G1 and the postmitotic
checkpoint (Andreassen et al., 2001; Lanni and Jacks, 1998; Sablina et al.,
1999). p21 is responsible for at least part of p53-mediated G1 and
postmitotic checkpoints (Khan and Wahl, 1998; Lanni and Jacks, 1998;
Stewart et al., 1999). Previous studies demonstrated that HPV-16 E7
overrides the tumor suppressive activities of p53 and p21 and
proliferate efﬁciently in the presence of elevated levels of p53 and p21
(Demers et al., 1994; Funk et al., 1997; Jones et al., 1997). Furthermore,
HPV-16 E7 overrides the tumor suppressor activity of p21 in a
transgenic model of cervical carcinogenesis (Shin et al., 2009). We
therefore examined the expression of p53 and p21 in HPV-58 E7
expressing PHKs. As shown in Fig. 4A, the steady-state levels of bothp53
and p21 were increased (for more than 3-fold) in E7 expressing PHKs,
despite the fact that theG1andpostmitotic checkpoints are abrogated in
these cells (Fig. 2). These results are consistent with previous
observation with HPV-16 E7 (Demers et al., 1994; Funk et al., 1997;
Jones et al., 1997) and suggest thatHPV-58E7, likeHPV-16E7, overrides
the tumor suppressor activity of p53 and p21.
Down-regulation of pRb and p130 in HPV-58 E7 expressing PHKs
It has been suggested that the ability of high-risk HPV E7 proteins to
bindanddestabilizepRb familymembers is necessary for abrogating the
G1 checkpoint (McLaughlin-Drubin and Munger, 2009). Our recent
study suggests a role of Rb inactivation in abrogating the postmitotic
checkpointbyHPV-16E7 (Heilmanet al., 2009).Wetherefore examined
the steady-state levels of pRb family members in HPV-58 E7 expressing
PHKsbyWesternblot. As shown inFig. 4B, theoverall steady-state levels
of pRb were reduced (for more than 1-fold) in PHK-58 E7 as compared
with the PHK-vector. Notably, the levels of pRbwere consistently higher
in PHK-58 E7 than in PHK-16 E7. Thus, the steady-state levels of pRb in
E7 expressing PHKs correlate with the ability of E7 to abrogate cell cycle
checkpoints. These results suggest that degradation of pRb is a
mechanism by which HPV-58 E7 regulate cell cycle checkpoints.
Surprisingly, the steady-state levels of p107 did not change
signiﬁcantly in PHKs expressing both HPV E7s as compared with thevector control PHKs (Fig. 4B). These results indicate that destabiliza-
tion of p107 does not play an important role in checkpoint abrogation
by HPV-58 E7, at least under our experimental conditions. On the
other hand, the steady-state levels of p130 were signiﬁcantly reduced
(for more than 2-fold) in PHK-58 E7 (Fig. 4B). Notably, the steady-
state levels of p130 in PHK-58 E7 were consistently and signiﬁcantly
lower than that of PHK-16 E7, despite the fact that HPV-58 E7 is less
efﬁcient in abrogating cell cycle checkpoints than HPV-16 E7 (Fig. 2).
The signiﬁcance of more efﬁcient p130 down-regulation by HPV-58
E7 remains to be explored. Taken together, the ability of HPV-58 E7 to
reduce the steady-state levels of pRb and p130, but not p107,
correlated with its ability to abrogate cell cycle checkpoints.
Discussion
A meta-analysis indicates that HPV-16 is more prevalent in
squamous cell carcinoma of the cervix (SCC) than high-grade
squamous intraepithelial lesions (HSIL), whereas the reverse is true
for other oncogenic types including HPV-58 (Clifford et al., 2003).
These data suggest that HSILs infected with HPV16 preferentially
progress to SCC while those infected with HPV-58 do not. The
mechanism for the difference is not well understood. More efﬁcient
down-regulation of pRb and abrogation of the cell cycle checkpoints
by HPV-16 E7 as compared with HPV-58 E7, as shown in this study,
may be a factor for the differential progression.
In contrast to what was previously observed, we did not detect a
signiﬁcant change in the steady-state levels of p107 in HPV-16 E7
expressing PHKs (Fig. 4B). We noticed that most of the previous
studies did not express HPV-16 E7 in keratinocytes and the results are
therefore not comparable. In the two studies where the steady-state
levels of p107 were examined in PHKs (Helt and Galloway, 2001;
Zhang et al., 2006), serum-free keratinocyte medium was used.
Keratinocyte culture condition may therefore play a role in destabi-
lization of p107 by E7. In support of this notion, it was shown that
HPV-16 E7 destabilized p107 in keratinocytes cultured in serum-free
but not in serum-containing medium (Zhang et al., 2006).
We have demonstrated in the present study that HPV-58 E7 is
more efﬁcient than HPV-16 E7 in down-regulation of p130. The
signiﬁcance of this observation is yet to be known. Two recent studies
have demonstrated that destabilization of p130 is the shared activity
of both low-risk and high-risk HPV E7s and plays a role in decreasing
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et al., 2008; Zhang et al., 2006). It is quite likely that down-regulation
of p130 contributes to the life cycle of HPV-58. It also remains possible
that down-regulation of p130 contributes to the ability of HPV-58 E7
to activate Cdk2, whose activity has been shown to be inhibited by
p130 ((Lacy and Whyte, 1997) and references therein). This may
explain why Cdk2 is equally active in PHKs expressing HPV-58 E7 or
HPV-16 E7, though they express different amount of pRb (Figs. 3B and
4A). A recent study showed that p130 blocks telomerase-independent
telomere lengthening (or alternative lengthening of telomeres (ALT))
(Kong et al., 2006). HPV-16 E7 extended the lifespan of PHKs in the
absence of telomerase (Stoppler et al., 1997). In normal human
embryonic ﬁbroblasts expressing HPV-16 E7, (Yamamoto et al., 2003)
demonstrated that telomere lengths were maintained by the
alternative lengthening of telomeres (ALT) mechanism. Here we
demonstrated that HPV-58 E7 signiﬁcantly extend the lifespan of
PHKs. It is therefore possible that down-regulation of p130 by HPV-58
E7 contributes to its ability to induce the extension of PHKs lifespan.
HPV-16 E7 overrides the tumor suppressor activity of p21 in a
transgenic model of cervical carcinogenesis (Shin et al., 2009). Several
mechanisms have been proposed for activation of Cdk2 by E7 in HPV-
infected tissues upon differentiation or DNA damage, where p21
expression is elevated (Zehbe et al., 1999). E7 was shown to associate
with cyclin/Cdk2 complexes, either directly or through pRb family
members ((McIntyre et al., 1996; Nguyen and Munger, 2008;
Tommasino et al., 1993) and references therein). It was suggested
and subsequently shown in vitro that the association of E7 with
cyclin/Cdk2 led to their activation (He et al., 2003). It was also
suggested that E7 bind and inhibit the functions of p21 (Funk et al.,
1997; Jones et al., 1997; Mansour et al., 2007).
However, others were unable to show efﬁcient E7/p21 interac-
tions (Hickman et al., 1997; Ruesch and Laimins, 1997; Westbrook et
al., 2002). Induction of S phase in differentiated human keratinocytes
in the presence of p21 does not appear to be a frequent event and only
occurs when high levels of E7 protein is induced (Banerjee et al.,
2006). Some studies suggest that E7 does not prevent p21-mediated
inhibition of cyclins/Cdk2 activity but work down-stream by
activating E2F1 (Morozov et al., 1997; Ruesch and Laimins, 1997).
While p21 is capable of inhibiting E2F activity in the absence of Rb
(Dimri et al., 1996), E7 can bind E2F1 and enhance E2F1 mediated
transcription (Hwang et al., 2002). On the other hand, E7 can also bind
E2F6 and abrogates the ability of E2F6 to repress transcription
(McLaughlin-Drubin et al., 2008). Notably, an E7-associated kinase
activity, which is not inhibited following DNA damage, has been
detected and shown to phosphorylate pRb (Hickman et al., 1997). The
identity of the E7-associated kinase remains to be characterized.
Another study showed that E7 prevents p21 nuclear accumulation to
retain cyclin E-Cdk2 activity in mouse NIH 3T3 cells (Westbrook et al.,
2002). The levels of cyclins A and E as well as Cdk2 are higher in E7
expressing cells ((Mansour et al., 2007) and references therein),
which may potentially increase the pool of p21-free Cdk2-associated
kinase. It remains to be determined the mechanism by which HPV-58
E7 activates Cdk2 in the presence of high levels of p21.
In summary, we observed several biological activities for HPV-58
E7 in PHKs. Down-regulation of pRb and p130 correlated with the
ability of HPV-58 E7 to abrogate cell cycle checkpoints and cervical
cancer progression. The mechanism by which HPV-58 E7 activates
Cdk2 in the presence of p21 remains to be explored.
Materials and methods
Cell culture
PHKs were derived from one neonatal human foreskin epithe-
lium obtained from the University of Massachusetts Memorial
Hospital as described (Liu et al., 2007). PHKs were maintained onmitomycin C-treated J2-3T3 feeder cells in F-medium composed of 3
parts Ham's F12 medium and 1 part Dulbecco's modiﬁed Eagle
medium (DMEM) plus 5% fetal bovine serum (FBS) with all supple-
ments as previously described (Flores et al., 2000). Amphotrophic
packaging cell line PA317 and J2-3T3 cells were maintained in DMEM
plus 10% FBS and antibiotics. To analyze the ability of E7 to extend the
lifespan of PHKs, 5×104 E7 expressing PHKs were seeded on 10-cm
dishes at each split. After they reached 80% conﬂuent, cells were split
and cell numbers were counted for calculating PDs versus time.
Retroviral infections
PHKs expressing HPV-16 E7 were described previously (Liu et al.,
2007). PHKs expressing HPV-58 E7 were established by retrovirus-
mediated infection using the pBabe Puro-based retroviral construct.
After puromycin selection, populations of infected cells were pooled
and maintained in puromycin-containing medium. HPV-58 E7
expression was conﬁrmed by RT-PCR using the following oligos:
HPV-58 E7, sense, 5′- ATGAGAGGAAACAACCCAAC-3′
HPV-58 E7, antisense, 5′-AGCTAGGGCACACAATGGTA-3′
β-Actin, sense, 5′-TGGCATTGCCGACAGGATGCAGAA-3′
β-Actin, antisense, 5′-CTCGTCATACTCCTGCTTGCTGAT-3′.
Immunoblotting and kinase assay
Protein extraction was performed in RIPA lysis buffer (150 mM
NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 50mM Tris–HCl,
pH 7.5, 5 mM EDTA, protease inhibitors (Complete EDTA-free, Roche).
Protein concentrations were determined by bicinchoninic acid (BCA)
analysis (Pierce). Equal amounts of protein from each cell lysate were
separated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and
transferred onto a PVDF membrane. The membranes were probed
with antibodies against pRb (BD Biosciences, 554136), p130 (BD
Biosciences, 610261), p107 (Santa Cruz, sc-318), p53 (Santa Cruz, sc-
126), p21 (BD Biosciences, 610234), Cdk2 (Santa Cruz, sc-6248), Cdk6
(Santa Cruz, sc-177), cyclin A (Santa Cruz, sc-751), cyclin E (Santa
Cruz, sc-198), and β-actin (Sigma, A2066). Immunoreactive proteins
were visualized with SuperSignal® West Pico chemiluminescent
substrate (Pierce). The membranes were scanned with an LAS-4000
Image Reader (Fuji Photo Film Inc.).
For kinase assay, cells were lysed in lysis buffer (50 mM HEPES, pH
7.5, 150 mM NaCl, 1 mM EDTA, 2.5 mM EGTA, 0.1%Tween 20, 1 mM
dithiothreitol, 10% glycerol, 0.1 mM phenylmethylsulfony ﬂuoride,
1 mM sodium ﬂuoride, 0.1 mM sodium orthovanadate and protease
inhibitor). 100 μgof total protein extractwere immunoprecipitatedwith
appropriate antibodies andproteinA/Gplus-agarose (SantaCruz). After
incubation for 4 hours at 4 °C, the beads were washed three times with
lysis buffer without glycerol and twice with kinase buffer (50 mM
HEPES, pH7.5, 10mMMgCl2, 1mMdithothreitol, 2.5mMEGTA, 0.1mM
sodium orthovanadate, 1 mM sodium ﬂuoride and protease inhibitor).
Assayswereperformed in thepresence of 10μCi of [γ-32P]ATP (3000Ci/
mmol, PerkeinElmer Life Sciences) and 20 μM ATP for 30 min at 30 °C.
1 μg of full length Rb (QED Bioscience Inc.) was used as substrate in each
reaction. Following the kinase reaction, samples were boiled in loading
buffer and separated by 8% SDS-PAGE. Phosphorylated proteins were
visualized by autoradiography.
Flow cytometry
Asynchronous cultures of cells were treated with DMSO (Sigma),
Bleomycin (Sigma, 10 μg/mL) or nocodazole (Sigma, 50 ng/mL). The
cellswereharvested,ﬁxed in 90%ethanol overnight, and resuspended in
a PBS-propidium iodide (PI, Sigma, 50 μg/mL)-RNase A (Sigma, 70 μg/
mL) solution. The PI stained cells were analyzed by ﬂow cytometry. Cell
cycle analysiswasperformedusing FlowJo software (BectonDickinson).
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Data were expressed as mean±standard deviation. Differences
between means were assessed by Student's t-test. p≤0.05 was
considered signiﬁcant.Acknowledgments
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